Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466686 · ClinicalTrials.gov registry record · Phase 2
Low Dose Radiation Therapy for Glioblastoma Multiforme
A Phase 2 study of High Grade Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 3
- Study locations
NCT01466686: Completed Phase 2 study of High Grade Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT01466686 is a Phase 2 study of High Grade Glioma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 31 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (52% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01466686, a Phase 2 study of High Grade Glioma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 3
- Study locations
Study Summary
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have previously been treated with surgery followed by radiation surgical resection followed by adjuvant radiation therapy plus temozolomide.
Primary Outcome
To estimate the response rate to salvage temozolomide plus LDFRT.
Conditions Studied
Interventions
- DRUG Temozolomide
- RADIATION Low Dose Fractionated Radiation Therapy (LDFRT)
Study Locations (3)
Maryland
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Suburban Hospital - Bethesda
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2012-09 |
| Est. Completion | 2022-12 |
| Phase | Phase 2 |
What the finished NCT01466686 record still lists
NCT01466686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (52% lower).
The record links to 1 condition, with High Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT01466686 reports a single indexed study location in Maryland, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01466686 about?
NCT01466686 is a clinical study titled "Low Dose Radiation Therapy for Glioblastoma Multiforme". To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have previously been treated with surgery followed by radiation surgical resection fo...
What is the current status of trial NCT01466686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2012-09. Estimated completion is 2022-12.
What conditions does trial NCT01466686 study?
This clinical trial studies the following conditions: High Grade Glioma.
What interventions are being tested in trial NCT01466686?
The interventions under investigation include: Temozolomide (DRUG), Low Dose Fractionated Radiation Therapy (LDFRT) (RADIATION).
Who is sponsoring clinical trial NCT01466686?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01466686 being conducted?
This trial has 3 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01466686's enrollment target sits among peer trials
31 23rd of 42 higher than 20 of 42 other High Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
RECRUITING · Phase 2
-
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
RECRUITING · Phase 2
-
Study of Olutasidenib and Temozolomide in HGG
RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia